Poster
T-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
A randomized Phase 3 study of first-line trastuzumab deruxtecan with rilvegostomig or pembrolizumab in patients with HER2-expressing, mismatch repair-proficient, primary advanced or recurrent endometrial cancer: DESTINY-Endometrial01/GOG-3098/ENGOT-EN24
Trine Jakobi Nøttrup
Poster
T-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) with bevacizumab (BEV) vs BEV monotherapy as first-line maintenance therapy in HER2-expressing ovarian cancer: DESTINY-Ovarian01 (DO-01, ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13)
Antonio J. González-Martín
Poster
T-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan versus standard of care chemotherapy with or without radiotherapy as adjuvant treatment for patients with HER2-expressing (IHC 3+/2+) endometrial cancer: DESTINY-Endometrial02 (DE-02; GOG-3122/ENGOT-en30)
Cara Mathews
Poster
R-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
Subgroup analysis of tumor response with raludotatug deruxtecan (R-DXd) by number and type of prior therapy in patients with platinum-resistant ovarian cancer in the Phase 2 part of REJOICE-Ovarian01
Isabelle Ray-Coquard
Poster
R-DXd
ESGO 2026 | February 26-28, 2026
Gynecologic Cancers
The experience of patients with platinum-resistant ovarian cancer: findings from a qualitative interview study in France, the UK, and the US
Florence Joly